JP2021528104A5 - - Google Patents
Info
- Publication number
- JP2021528104A5 JP2021528104A5 JP2021520275A JP2021520275A JP2021528104A5 JP 2021528104 A5 JP2021528104 A5 JP 2021528104A5 JP 2021520275 A JP2021520275 A JP 2021520275A JP 2021520275 A JP2021520275 A JP 2021520275A JP 2021528104 A5 JP2021528104 A5 JP 2021528104A5
- Authority
- JP
- Japan
- Prior art keywords
- heterogeneous
- antibody
- enables
- extension
- life
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024016792A JP7741574B2 (ja) | 2018-06-22 | 2024-02-07 | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862689051P | 2018-06-22 | 2018-06-22 | |
| US62/689,051 | 2018-06-22 | ||
| PCT/US2019/038210 WO2019246379A1 (en) | 2018-06-22 | 2019-06-20 | Novel interleukin-15 (1l-15) fusion proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024016792A Division JP7741574B2 (ja) | 2018-06-22 | 2024-02-07 | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528104A JP2021528104A (ja) | 2021-10-21 |
| JP2021528104A5 true JP2021528104A5 (enExample) | 2022-06-23 |
| JP7440102B2 JP7440102B2 (ja) | 2024-02-28 |
Family
ID=68984274
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021520275A Active JP7440102B2 (ja) | 2018-06-22 | 2019-06-20 | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
| JP2024016792A Active JP7741574B2 (ja) | 2018-06-22 | 2024-02-07 | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024016792A Active JP7741574B2 (ja) | 2018-06-22 | 2024-02-07 | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12319722B2 (enExample) |
| EP (1) | EP3810171B1 (enExample) |
| JP (2) | JP7440102B2 (enExample) |
| KR (2) | KR20250130696A (enExample) |
| CN (2) | CN121086085A (enExample) |
| AU (2) | AU2019288471B2 (enExample) |
| CA (1) | CA3102821A1 (enExample) |
| WO (1) | WO2019246379A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU24546B1 (es) * | 2016-12-30 | 2021-09-07 | Ct Ingenieria Genetica Biotecnologia | Composición vacunal que comprende un mutante de la interleucina-15 humana |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN109705211B (zh) | 2017-10-26 | 2020-08-18 | 苏州复融生物技术有限公司 | 一种IgG1 Fc单体及其应用 |
| CN113286812B (zh) | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| KR20220114063A (ko) * | 2019-12-13 | 2022-08-17 | 큐진 인크. | 신규한 인터루킨-15 (ｉｌ-15) 융합 단백질 및 이의 용도 |
| AU2021260989A1 (en) * | 2020-04-22 | 2022-11-17 | Novartis Ag | Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetIL-15) |
| KR20250140647A (ko) * | 2020-08-03 | 2025-09-25 | 난트셀, 인크. | Il-15 초작용제에 대한 약물-특이적 약동학 검정 |
| EP4206219A1 (en) * | 2020-08-31 | 2023-07-05 | GI Cell, Inc. | Fusion protein including il15 protein, il15 receptor alpha protein, fc domain, and il2 protein, and use thereof |
| KR20230104866A (ko) * | 2020-09-16 | 2023-07-11 | 베이진 엘티디 | 인터류킨 15 작제물 및 사용 방법 |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| CN113321736B (zh) * | 2020-12-30 | 2024-01-09 | 苏州复融生物技术有限公司 | 一种长效化白介素15融合蛋白及其制备方法和应用 |
| US20250197525A1 (en) * | 2021-04-28 | 2025-06-19 | Minotaur Therapeutics, Inc. | Humanized chimeric bovine antibodies and methods of use |
| CN116375888A (zh) * | 2021-05-08 | 2023-07-04 | 上海交通大学 | 一种融合蛋白及其制备方法和用途 |
| EP4346875A4 (en) * | 2021-05-28 | 2025-04-16 | Akso Biopharmaceutical, Inc. | BISPECIFIC FC FUSION PROTEINS WITH SPD-1 AND IL-15 |
| CN116655771A (zh) * | 2021-05-28 | 2023-08-29 | 苏州复融生物技术有限公司 | 一种新型白介素15突变体多肽的开发及其应用 |
| US20240350589A1 (en) | 2021-08-13 | 2024-10-24 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| CN116023503B (zh) * | 2021-10-25 | 2024-05-31 | 上海交通大学 | 一种融合蛋白及其制备方法和用途 |
| EP4435011A4 (en) * | 2021-11-15 | 2025-07-16 | Inst Biophysics Cas | FUSION PROTEIN CONSTRUCTION TAKING INTERLEUKIN 15 AS ACTIVE INGREDIENT AND USE THEREOF |
| CN115141283A (zh) * | 2022-03-10 | 2022-10-04 | 厦门柏慈生物科技有限公司 | 一种融合蛋白、制备方法及其应用 |
| WO2024039973A2 (en) * | 2022-08-05 | 2024-02-22 | Staidson Biopharma Inc. | Masking polypeptide, activatable novel prodrugs and methods of use thereof |
| WO2024091794A1 (en) * | 2022-10-28 | 2024-05-02 | Nant Holdings IP, LLP | Vaccine composition for stimulation of broad-spectrum memory of b cell expansion |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| KR20050049545A (ko) * | 2002-10-14 | 2005-05-25 | 에프. 호프만-라 로슈 아게 | 길항제 ｉｌ-15 |
| ES2367027T3 (es) | 2004-02-27 | 2011-10-27 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista. |
| US20060257361A1 (en) | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| EP2173378B1 (en) | 2007-06-27 | 2014-03-19 | Admune Therapeutics LLC | Complexes of il-15 and il-15ralpha and uses thereof |
| JP6251570B2 (ja) * | 2010-09-21 | 2017-12-20 | アルター・バイオサイエンス・コーポレーション | 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法 |
| BR112015006824A2 (pt) | 2012-09-27 | 2017-07-04 | Merus B V | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico |
| US20150359853A1 (en) * | 2012-10-24 | 2015-12-17 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| EP3093295B1 (en) | 2014-01-08 | 2020-05-27 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Il-15 heterogeneous dimer protein and uses thereof |
| US10335460B2 (en) | 2014-07-29 | 2019-07-02 | Novartis Ag | IL-15 and IL-15Rα heterodimer dose escalation regimens for treating conditions |
| US10905743B2 (en) | 2014-12-19 | 2021-02-02 | Jiangsu Hengrui Medicine Co., Ltd. | Interleukin 15 protein complex |
| CN112574316A (zh) | 2015-07-02 | 2021-03-30 | 博际生物医药科技(杭州)有限公司 | 用于肿瘤靶向治疗的白细胞介素-15融合蛋白 |
| US10858452B2 (en) * | 2015-09-16 | 2020-12-08 | Insitut National de la Sante et de la Recherche Medicale (INSERM) | Specific interleukin-15 (IL-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
| MX2019004327A (es) | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
-
2019
- 2019-06-20 CN CN202511239681.1A patent/CN121086085A/zh active Pending
- 2019-06-20 AU AU2019288471A patent/AU2019288471B2/en active Active
- 2019-06-20 WO PCT/US2019/038210 patent/WO2019246379A1/en not_active Ceased
- 2019-06-20 KR KR1020257027222A patent/KR20250130696A/ko active Pending
- 2019-06-20 EP EP19822948.6A patent/EP3810171B1/en active Active
- 2019-06-20 KR KR1020217002145A patent/KR102848197B1/ko active Active
- 2019-06-20 JP JP2021520275A patent/JP7440102B2/ja active Active
- 2019-06-20 CA CA3102821A patent/CA3102821A1/en active Pending
- 2019-06-20 US US17/254,004 patent/US12319722B2/en active Active
- 2019-06-20 CN CN201980055119.XA patent/CN112584851B/zh active Active
-
2024
- 2024-02-07 JP JP2024016792A patent/JP7741574B2/ja active Active
-
2025
- 2025-02-19 AU AU2025201175A patent/AU2025201175A1/en active Pending
- 2025-05-03 US US19/197,991 patent/US20250388641A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023526975A5 (enExample) | ||
| EP3765522A4 (en) | ANTI-CLAUDIN 18.2 ANTIBODIES | |
| CN113316591A (zh) | Cd73抗体及其制备方法和应用 | |
| JP2017534262A5 (enExample) | ||
| JP2022122972A5 (enExample) | ||
| JP2022185040A5 (enExample) | ||
| JP2024026077A5 (enExample) | ||
| JP2020532288A5 (enExample) | ||
| JP2023182571A5 (enExample) | ||
| JP2023133317A5 (enExample) | ||
| JP2022505925A5 (enExample) | ||
| JP2018186833A5 (enExample) | ||
| JP2022064180A5 (enExample) | ||
| JP2020079331A5 (enExample) | ||
| JP2023116477A5 (enExample) | ||
| HRP20251693T1 (hr) | Poboljšana sinteza 1,4-diazaspiro[5.5]undekan-3-ona | |
| JP2023012502A5 (enExample) | ||
| IL286306A (en) | Manufacturing methods for producing anti-tnf antibody compositions | |
| JP2023145479A5 (enExample) | ||
| JP2023078311A5 (enExample) | ||
| JOP20210100A1 (ar) | جسم مضاد أحادي النسيلة يرتبط على وجه التحديد بـ cd20 | |
| JP2015119721A5 (enExample) | ||
| JPWO2021132591A5 (enExample) | ||
| JP2022506891A5 (enExample) | ||
| JP2020531778A5 (enExample) |